

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

October 19, 2022

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2020/1_DrSwees_premeeting_announcement.pdf
- II. Roll Call
- III. Review of meeting transcript for July 13, 2022, meeting
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/07-13-22_DURB_meeting_transcript_upd.pdf
- IV. Review of draft meeting summary for July 13, 2022, meeting
- V. Secretary's report
- VI. Old Business
 - A. Ivermectin utilization report (January – July 2022)
 - B. MCO'S response to DUR PA report/State's chum report rate report
 - C. Addendum to calcitonin gene-related peptide (CGRP) receptor antagonists protocol
 - D. Summary of DURB suggested changes to proposed protocols (see links to protocols below)
 - i. Vuity® (pilocarpine ophthalmic)
 - ii. Complement inhibitor products or PNH (Soliris®, Empaveli®, Ultomiris®)
 - iii. Bylvay® (odevixibat)
 - E. Proposed protocol for Vuity® (pilocarpine ophthalmic)
 - F. Proposed protocol for complement inhibitor products (Soliris®, Empaveli®, Ultomiris®)
 - G. Proposed protocol for Bylvay® (odevixibat)
 - H. Semaglutide utilization for weight loss (Wegovy) [July 2021 thru June 2022]
- VII. New Business
 - A. Proposed protocol for Glucagon-like peptide 1 (GLP-1) agonists used in T2D
 - B. Proposed protocol for Zynteglo® (betibeglogene autotemcel)
 - C. Proposed protocol for Cholbam® (cholic acid)
 - D. Proposed protocol for Crysvita® (burosumab)
- VIII. DURB Annual Summary Review for SFY 2022 (Board members only)
- IX. A. Informational Highlights/Reports
 - 1. Gainwell Technologies/NJ HMO 2nd Quarter 2022 Prior Authorization Report
 - 2. Summary of DURB Action Items

3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)

FFS:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/FFS_Top_Drugs_Report_Aug-2022.xlsx

MCO:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/MCO_Top_Drugs_Report_Jul-2022.xlsx

FFS category:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/FFS_Top_Drugs_by_Category_Aug-2022.xlsx

MCO category:

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/MCO_Top_Drugs_by_Category_Jul-2022.xlsx

- (b) Antiviral drugs by amount paid

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/FFS_Antiviral_Drugs_Aug-2022.xlsx

B. Medication information:

1. COVID-19 Vaccines information

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html> Continuously updated.

3. New Jersey COVID-19 Information Hub (continuously updated)

<https://covid19.nj.gov/>

4. New Jersey COVID-19 Dashboard

https://www.nj.gov/health/cd/topics/covid2019_dashboard.shtml continuously updated

5. Know Your Treatment Options for COVID-19 – FDA

<https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19>

X. Updated Materials:

- a. Proposed protocol for Vuity® (pilocarpine ophthalmic) – approved July 2022

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/Vuity_Approved_Protocol.pdf

- b. Proposed protocol for complement inhibitor products (Soliris®, Empaveli®, Ultomiris®) – approved July 2022

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/PNH_products_approved_protocol.pdf

- c. Proposed protocol for Bylvay® (odevixibat) – approved July 2022

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2022/Bylvay_Approved_Protocol.pdf